Kanada - İngilizce - Health Canada

aventis pasteur limited - diphtheria toxoid; inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett; tetanus toxoid; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney - suspension - 25lf; 8unit; 32unit; 5lf; 40unit - diphtheria toxoid 25lf; inactivated poliomyelitis vaccine (d.c.o.) type 2 mef1 8unit; inactivated poliomyelitis vaccine (d.c.o.) type 3 saukett 32unit; tetanus toxoid 5lf; inactivated poliomyelitis vaccine (d.c.o.) type 1 mahoney 40unit - vaccines

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - polio virus type 1 40 dagu; polio virus type 2 8 dagu; polio virus type 3 32 dagu - solution for injection - active: polio virus type 1 40 dagu polio virus type 2 8 dagu polio virus type 3 32 dagu excipient: albumin formaldehyde phenoxyethanol

Kanada - İngilizce - Health Canada

aventis pasteur limited - poliomyelitis vaccine (inactivated); tetanus toxoid - liquid - 80unit; 5unit - poliomyelitis vaccine (inactivated) 80unit; tetanus toxoid 5unit - toxoids

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

sanofi-aventis new zealand limited - polio virus type 1 300000 tcid50; polio virus type 2 100000 tcid50; polio virus type 3 300000 tcid50 - oral suspension - 0.5 ml - active: polio virus type 1 300000 tcid50 polio virus type 2 100000 tcid50 polio virus type 3 300000 tcid50 excipient: albumin magnesium chloride hexahydrate phenolsulfonphthalein

Tanzanya - İngilizce - Tanzania Medicinces & Medical Devices Authority

bilthoven biologicals, netherlands - poliomyelitis, trivalent, inactivated, whole virus - suspension for injection - -

Malta - İngilizce - Medicines Authority

smithkline beecham limited - pertactin; pertussis filamentous haemagglutinin; pertussis toxoid; poliovirus (inactivated) type 1 (mahoney strain); poliovirus (inactivated) type 2 (mef-1 strain); poliovirus (inactivated) type 3 (saukett strain); diphtheria toxoid; haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate); tetanus toxoid - powder and suspension for suspension for injection - pertactin 8 µg; pertussis filamentous haemagglutinin 25 µg; pertussis toxoid 25 µg; poliovirus (inactivated) type 1 (mahoney strain) 40 dagu/0.5ml; poliovirus (inactivated) type 2 (mef-1 strain) 8 dagu/0.5ml; poliovirus (inactivated) type 3 (saukett strain) 32 dagu/0.5ml; diphtheria toxoid; haemophilus influenzae type b polysaccharide (polyribosylribitol phosphate) 10 µg; tetanus toxoid - vaccines

Avrupa Birliği - İngilizce - EMA (European Medicines Agency)

glaxosmithkline biologicals s.a. - diphtheria toxoid, tetanus toxoid, bordetella pertussis antigens (pertussis toxoid, filamentous haemagglutinin, pertactin), hepatitis b surface antigen, poliovirus (inactivated) (type-1 (mahoney strain), type-2 (mef-1 strain), type-3 (saukett strain)), haemophilus influenzae type b polysaccharide - hepatitis b; tetanus; immunization; meningitis, haemophilus; whooping cough; poliomyelitis; diphtheria - vaccines - infanrix hexa is indicated for primary and booster vaccination of infants against diphtheria, tetanus, pertussis, hepatitis b, poliomyelitis and disease caused by haemophilus influenzae type-b.

Bangladeş - İngilizce - DGDA (Directorate General of Drug Administration)

incepta pharmaceuticals ltd., vaccine division - poliomyelitis vacine, live (oral) - vaccine - .1 ml/.1 ml

Singapur - İngilizce - HSA (Health Sciences Authority)

sanofi-aventis singapore pte. ltd. - (acellular pertussis) filamentous haemagglutinin adsorbed (fha); (acellular pertussis) fimbriae type 2 and 3 adsorbed (fim); (acellular pertussis) pertactin adsorbed (prn); (acelullar pertussis) pertussis toxoid adsorbed (pt); diphtheria toxoid adsorbed; inactivated poliomyelitis vaccine (ipv) type 1 mahoney; inactivated poliomyelitis vaccine (ipv) type 2 (mef-1); inactivated poliomyelitis vaccine (ipv) type 3 (saukett); tetanus toxoid adsorbed - injection, suspension - (acellular pertussis) filamentous haemagglutinin adsorbed (fha) 5 µg/ 0.5 ml; (acellular pertussis) fimbriae type 2 and 3 adsorbed (fim) 5 µg/0.5 ml; (acellular pertussis) pertactin adsorbed (prn) 3 µg/0.5 ml; (acelullar pertussis) pertussis toxoid adsorbed (pt) 2.5 µg/ 0.5 ml; diphtheria toxoid adsorbed 2lf; inactivated poliomyelitis vaccine (ipv) type 1 mahoney 40 d-antigen units; inactivated poliomyelitis vaccine (ipv) type 2 (mef-1) 8 d-antigen units; inactivated poliomyelitis vaccine (ipv) type 3 (saukett) 32 d-antigen units; tetanus toxoid adsorbed 5lf

Yeni Zelanda - İngilizce - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - diphtheria toxoid, adsorbed 2 [iu] (nlt, equiv to 2 lf per dose); pertactin 3ug; pertussis filamentous haemagglutinin 5ug; pertussis fimbriae 2+3 5ug; pertussis toxoid, adsorbed 2.5ug; polio virus type 1 29 dagu (mahoney, by parallel line method (equiv to 40 dagu by sigmoid method)); polio virus type 2 7 dagu (mef 1, by parallel line method (equiv to 8 dagu by sigmoid method)); polio virus type 3 26 dagu (saukett, by parallel line method (equiv to 32 dagu by sigmoid method)); tetanus toxoid 20 [iu] (nlt, equiv to 5 lf per dose) - suspension for injection - 0.5 ml - active: diphtheria toxoid, adsorbed 2 [iu] (nlt, equiv to 2 lf per dose) pertactin 3ug pertussis filamentous haemagglutinin 5ug pertussis fimbriae 2+3 5ug pertussis toxoid, adsorbed 2.5ug polio virus type 1 29 dagu (mahoney, by parallel line method (equiv to 40 dagu by sigmoid method)) polio virus type 2 7 dagu (mef 1, by parallel line method (equiv to 8 dagu by sigmoid method)) polio virus type 3 26 dagu (saukett, by parallel line method (equiv to 32 dagu by sigmoid method)) tetanus toxoid 20 [iu] (nlt, equiv to 5 lf per dose) excipient: aluminium phosphate ethanol phenoxyethanol polysorbate 80 water for injection - adacel® polio is indicated for active immunisation against diphtheria, tetanus, pertussis and poliomyelitis in adults, adolescents and children aged 4 years and older as a booster following primary immunisation. children 4-6 years of age should have already received four doses of dtpa and ipv or opv. adacel® polio is not intended for primary immunisation. adacel® polio may be administered during pregnancy for prevention of pertussis in young infants via transplacental antibody transfer from the pregnant woman to the fetus. the use of adacel® polio should be determined on the basis of official recommendations.